Nov 01, 2007, 04.03 PM | Source:

Dabur Pharma receives USFDA approval for generic Irinotecan

Dabur Pharma receives USFDA approval for generic Irinotecan

Dabur Pharma Ltd. (NSE: DABURPHARM, BSE: 532545), India’s leading oncology player, today announced that the US Food and Drug Administration (USFDA) has granted tentative approval to the Company’s Abbreviated New Drug Application (ANDA) to market it’s generic version of Pfizer’s Camptosar (Irinotecan Hydrochloride) Injection 40mg and 100mg.


Irinotecan, which had sales of over US$ 500 million in the US (IMS - MAT 03/07), is indicated as a component of first line therapy in combination with 5- fluorouracil and leucovorin for the patients with metastatic carcinoma of the colon or rectum. Irinotecan is also indicated for the patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil- based therapy.


The Company said that it expects to begin marketing the drug in US upon expiry of the patent in February 2008.


Speaking on the occasion, Ajay Kumar Vij, CEO, Dabur Pharma said that “this marks a major milestone for Dabur Pharma, which is vertically integrated in the product and is already one of the largest producers of Irinotecan API (Active Pharmaceutical Ingredient) in the world.  The Company is one of the most cost effective producers of Irinotecan in the world and the approval & subsequent launch will provide a quantum jump to our aggressive growth plans”.

Sourced From : Imprimis Life PR Pvt Ltd

Fresenius Kabi stock price

On , 0, Fresenius Kabi Oncology closed at Rs 132.45, up Rs 0.00, or 0.00 percent. The 52-week high of the share was Rs 161.40 and the 52-week low was Rs 93.10.

The latest book value of the company is Rs 42.55 per share. At current value, the price-to-book value of the company was 3.11.

Set email alert for


video of the day

Nifty to fall below 7500 if Q3 disappoints; GST key: Kumar

Explore Moneycontrol

Copyright © Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of is prohibited.